Johnson & Johnson (JNJ) earnings on July 15, 2026
More Johnson & Johnson earnings
Prior outlook: No statistical edge
Johnson & Johnson shares declined even after raising its 2026 outlook and reporting growth beyond its main drugs.
JNJ price around the earnings
247.02
Change: -2.6%
2026-07-15, 20:00 UTC
Start of the measured window
End of the measured window
246.18
250.09
254.00
257.91
253.60
July 15, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: No statistical edge
- Thesis published
Strong 30d trend (+12.67%) with solid earnings history but recent trajectory deteriorating and retail crowding elevated.
Context analyzed before publication
- Trend
- Volatile run-up into event, showing strong trend strength but also recent unwinding from after a strong recent rise conditions.
Analysts
Evidence
- Analyst moves in the last 60 days
- 6
- Strong buy: 5
- Buy: 10
- Hold: 7
- Sell: 1
- Strong sell: 0
- Strong buy
- 5
- Buy
- 10
- Hold
- 7
- Sell
- 1
- Strong sell
- 0
- July 13, 2026 · TD Cowen: Maintains rating (Buy → Buy)
- July 13, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- July 10, 2026 · B of A Securities: Maintains rating (Neutral → Neutral)
- July 8, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- July 8, 2026 · Citigroup: Maintains rating (Buy → Buy)
- June 26, 2026 · Guggenheim: Maintains rating (Buy → Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (6)
- Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday — Benzinga
- Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’ — Benzinga
- How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings — Benzinga
- TD Cowen Maintains Buy on Johnson & Johnson, Raises Price Target to $300 — Benzinga
- RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $287 — Benzinga
- B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $263 — Benzinga
Technicals
Evidence
- Average true range (ATR)
- 2.3%
- Distance to 52-week high
- -5.0%
- 14-day change (14d)
- +6.1%
- 30-day change (30d)
- +12.7%
- 30-day relative strength
- +12.7%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 253.1
- Nearest resistance
- 255
- Volume accumulation ratio (14d / 46d)
- 1.05
Trends
Evidence
- Average earnings surprise
- +1.4%
- April 14, 2026: actual EPS 2.7 vs estimate 2.68 (surprise +0.8%)
- January 21, 2026: actual EPS 2.46 vs estimate 2.46 (surprise -0.1%)
- October 14, 2025: actual EPS 2.8 vs estimate 2.76 (surprise +1.5%)
- July 16, 2025: actual EPS 2.77 vs estimate 2.68 (surprise +3.2%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 1.7%
- 75th percentile move
- 2.7%
- 90th percentile move
- 4.2%
- Up / down moves
- 9 / 10
- Average up move
- +3.0%
- Average down move
- -1.2%
Monitoring and close
What Johnson & Johnson reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Consolidated
- -2.9%
- Max move
- -3.0%
No verdict: the outlook took no direction, so there is nothing to score as a hit or a miss.